Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 07:00 ET | Source: BPGbio

BPGbio Wins 2025 AI Drug Development Innovation Award from Biotech Breakthrough Awards

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won...
November 05, 2025 11:22 ET | Source: Research and Markets

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, End Point Status

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) - Global Clinical Trials Review, 2025" clinical trials has been added to ...
October 16, 2025 07:00 ET | Source: BPGbio

BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...
October 09, 2025 07:04 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

60 Degrees Pharma unveils “B-FREE” Phase 2 trial for chronic babesiosis, engaging patients in naming and supporting Lyme research groups.
September 04, 2025 07:00 ET | Source: BPGbio

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM) and Topline Phase 2b clinical data expected in 1H 2026
July 21, 2025 07:23 ET | Source: Research and Markets

CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 | CD5 Therapies Reach Phase-II Trials with Less Than 10 in Pipeline

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report has been added to ...
May 13, 2025 09:15 ET | Source: BioRestorative Therapies, Inc

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on...
February 27, 2025 09:45 ET | Source: BioRestorative Therapies, Inc

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline...
January 31, 2025 05:00 ET | Source: Research and Markets

CD70 Targeting Therapies Clinical Trials Insight 2025: 20+ CD70 Targeting Therapies In Clinical Trials

Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's offering. CD70...
November 01, 2023 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) --...